- Home
- NBIX vs REG Comparison
NBIX vs REG Comparison
Compare NBIX & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBIX | REG |
|---|---|---|
| Founded | 1992 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 12.8B |
| IPO Year | 1996 | 1993 |
Fundamental Metrics
Financial Performance| Metric | NBIX | REG |
|---|---|---|
| Price | $155.51 | $68.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 11 |
| Target Price | ★ $173.79 | $78.90 |
| AVG Volume (30 Days) | 969.9K | ★ 1.1M |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 4.40% |
| EPS Growth | ★ 12.44 | 2.61 |
| EPS | ★ 4.19 | 2.18 |
| Revenue | ★ $2,682,700,000.00 | $1,576,868,000.00 |
| Revenue This Year | $23.76 | $3.11 |
| Revenue Next Year | $18.01 | $4.13 |
| P/E Ratio | $37.10 | ★ $31.52 |
| Revenue Growth | ★ 19.61 | 5.84 |
| 52 Week Low | $84.23 | $63.44 |
| 52 Week High | $157.67 | $78.18 |
Technical Indicators
Market Signals| Indicator | NBIX | REG |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 37.54 |
| Support Level | $150.26 | $70.64 |
| Resistance Level | $154.35 | $71.75 |
| Average True Range (ATR) | 4.16 | 1.02 |
| MACD | 1.07 | -0.10 |
| Stochastic Oscillator | 93.25 | 3.37 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.